Active Ingredient History
Figitumumab is a monoclonal antibody targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC). Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2)
Carcinoma, Adenosquamous (Phase 3)
Carcinoma, Large Cell (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Colorectal Neoplasms (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Lung Neoplasms (Phase 1)
Multiple Myeloma (Phase 1)
Neoplasms (Phase 1)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 1)
Sarcoma, Ewing (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue